2019年冠状病毒病(COVID-19)已成为全球大流行。社区和密切接触暴露继续推动COVID-19大流行。对疑似病例和密切接触者尚无确诊的有效治疗方法。目前市场上的再利用中药产品莲花清瘟(LH)胶囊,已被证明对流感和COVID-19有效。
为了确定LH胶囊预防COVID-19的安全性和有效性,我们对与COVID-19感染者密切接触的受试者进行了LH胶囊的前瞻性开放标签对照试验。受试者接受LH胶囊(4粒胶囊,每日3次)或常规医学观察14天。主要终点是检疫医学观察期间鼻拭子和咽拭子核酸检测阳性率。我们纳入1976例患者,其中治疗组1101例,对照组875例。核酸检测阳性率治疗组明显低于对照组(分别为0.27% vs. 1.14%;均数差:-0.87%;95%CI:-1.83~-0.13;p = 0.0174)。在不同密切接触状态的受试者中,治疗组和对照组中密切接触者的核酸检测结果阳性率无显著差异(分别为6.45% vs. 11.43%;p = 0.6762)。在次要密切接触者中,治疗组的核酸检测阳性率显著低于对照组(分别为0.09%和0.71%;p = 0.0485)。未报告严重不良事件。综上所述,根据安全性和有效性特征,这些结果表明LH胶囊可被认为在与感染者密切接触后可预防COVID-19的进展。-本试验已在ChiCTR2100043012注册。
Coronavirus disease 2019 (COVID-19) has become a global pandemic. Community and close contact exposures continue to drive the COVID-19 pandemic. There is no confirmed effective treatment for suspected cases and close contacts. Lianhuaqingwen (LH) capsules, a repurposed Chinese herbal product that is currently on the market, have proven effective for influenza and COVID-19.
To determine the safety and efficacy of LH capsules for the prevention of COVID-19, we conducted a prospective open-label controlled trial of LH capsules on subjects who had close contact with people infected with COVID-19. Subjects received LH capsules (4 capsules, three times daily) or the usual medical observation for 14 days. The primary endpoint was the rate of positive nucleic acid tests of nasal and pharyngeal swabs during the quarantine medical observation period. We included 1976 patients, including 1101 in the treatment group and 875 in the control group. The rate of positive nucleic acid tests in the treatment group was significantly lower than that in the control group (0.27% vs. 1.14%, respectively; mean difference: −0.87%; 95% CI: −1.83 to −0.13; p = 0.0174) during the quarantine medical observation period (14 days). Among subjects with different close contact states, there was no significant difference in the rate of positive nucleic acid test results among close contacts in the treatment group and the control group (6.45% vs. 11.43%, respectively; p = 0.6762). Among secondary close contacts, the rate of positive nucleic acid tests in the treatment group was significantly lower than that in the control group (0.09% vs. 0.71%, respectively; p = 0.0485). No serious adverse events were reported. Taken together, and in light of the safety and effectiveness profiles, these results show that LH capsules can be considered to prevent the progression of COVID-19 after close contact with an infected person. This trial is registered with ChiCTR2100043012.
最终得出,LH胶囊对暴露于COVID-19患者具有预防作用。根据其有效性和安全性特征,认为LH胶囊可用于预防暴露后的COVID-19。未来需要进行双盲、前瞻性、随机对照试验,以充分评价LH胶囊在更大患者人群中的疗效。
注:
本文为节选部分翻译,全篇完整内容链接如下:https://www.hindawi.com/journals/ecam/2021/7962630/。
全文由爱特曼云翻译平台翻译而成,欢迎使用与指正!
试用链接:https://fanyi.atman360.com/text